Abstract #3815
Spectroscopic imaging with hyperpolarized [1- 13 C]pyruvate shows an elevated lactate/pyruvate ratio in contrast enhancing and non-enhancing brain tumors of orthotopic patient-derived xenograft models of glioblastoma.
Richard Mair 1,2 , Alan Wright 1 , Kieren Allinson 3 , Tiago Rodrigues 1 , Colin Watts 2 , and Kevin Brindle 1
1
CRUK Cambridge Institute, University of
Cambridge, Cambridge, Cambridgeshire, United Kingdom,
2
Division
of Neurosurgery, University of Cambridge, Cambridge,
Cambridgeshire, United Kingdom,
3
Department
of Pathology, Cambridge University Hospitals NHS
Foundation Trust, Cambridgeshire, United Kingdom
Glioblastoma is the most common
human-primary-intracranial neoplasm and has the worst
prognosis. Novel orthotopic patient-derived xenograft
models that recapitulate the pathophysiological
phenotype of the disease allow development of novel
imaging modalities for downstream clinical applications
in treatment planning and monitoring. We demonstrate
that
13
C
magnetic resonance spectroscopic imaging with
hyperpolarized [1-
13
C]pyruvate shows the
presence of tumor through an elevated lactate/pyruvate
ratio in both contrast enhancing and non-enhancing brain
tumor lesions including areas where tumor is
undetectable on T
2
weighted MRI but present on
histology.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
